NTRK FusionSEQ Panel

Test Code
12352


Preferred Specimen
**This test is not available for New York or Rhode Island
patient testing.**
Instructions:
Do not freeze. Do not reject.
Submit in sterile biohazard plastic bag at room temperature
or on ice pack in summer. Specimen to be tested should
contain a minimum of 10 percent tumor nuclei.
All specimens must be accompanied with Pathology report.
All FFPE specimens will be examined by a pathologist for
confirmation and adequacy. Macrodissection if warranted is
performed in the lab.
Reject Criteria:
Decalcified tissue specimen
PREFERRED
6-10 slides (10-micron sections) for resection or surgical
specimens with H&E slide in slide holder, room temperature
or refrigerated (cold packs)
--or--
10-20 slides (10-micron sections) for core needle biopsies
in slide holder, room temperature or refrigerated (cold
packs)
--or--
ACCEPTABLE
Paraffin-embedded tissue block accompanied by a circled H&E
slide indicating the area to be examined, room temperature
or refrigerated (cold packs)
RT: Preferred
Refrigerated (cold packs): Acceptable
Frozen: Unacceptable


Methodology
Next Generation Sequencing Multiplex Polymerase Chain Reaction

Setup Schedule
Monday-Sunday Morning
Report available: 11 Days


Reference Range
See Laboratory Report


Clinical Significance
The NTRK FusionSEQ assay will detect the presence of gene
rearrangements (fusions) in NTRK1, NTRK2 and NTRK3.
FDA-approved therapies and clinical trials are available
for patients with these genomic abnormalities in certain
solid tumors, and the detection of these abnormalities is
beneficial in the management of disease and survival of
the patient.




The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.